MX2022011518A - Metodos para tratar deambulacion asociada a proteinopatia. - Google Patents
Metodos para tratar deambulacion asociada a proteinopatia.Info
- Publication number
- MX2022011518A MX2022011518A MX2022011518A MX2022011518A MX2022011518A MX 2022011518 A MX2022011518 A MX 2022011518A MX 2022011518 A MX2022011518 A MX 2022011518A MX 2022011518 A MX2022011518 A MX 2022011518A MX 2022011518 A MX2022011518 A MX 2022011518A
- Authority
- MX
- Mexico
- Prior art keywords
- proteinopathy
- wandering
- patients
- treating
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000003590 rho kinase inhibitor Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010029350 Neurotoxicity Diseases 0.000 abstract 1
- 206010044221 Toxic encephalopathy Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 230000007135 neurotoxicity Effects 0.000 abstract 1
- 231100000228 neurotoxicity Toxicity 0.000 abstract 1
- 230000007425 progressive decline Effects 0.000 abstract 1
- 230000004845 protein aggregation Effects 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se basa en el descubrimiento de que se pueden usar inhibidores de la quinasa rho para tratar la deambulación asociada a proteinopatía. Se cree que una cantidad de enfermedades neurológicas degenerativas son causadas, al menos en parte, por la formación de agregados de proteínas que provocan neurotoxicidad y deterioro progresivo de las funciones. Los métodos inventivos se refieren al uso de inhibidores de la quinasa rho para tratar a pacientes con deambulación asociada a proteinopatía. Los pacientes pueden padecer de enfermedad de Huntington, una lesión cerebral traumática, trastorno del espectro autista, síndrome de Down o una demencia asociada a proteinopatía, tal como enfermedad de Alzheimer o demencia frontotemporal.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062994527P | 2020-03-25 | 2020-03-25 | |
| US202063005913P | 2020-04-06 | 2020-04-06 | |
| PCT/US2021/012587 WO2021194608A1 (en) | 2020-03-25 | 2021-01-08 | Methods of treating proteinopathy- associated wandering |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011518A true MX2022011518A (es) | 2022-10-07 |
Family
ID=77855102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011518A MX2022011518A (es) | 2020-03-25 | 2021-01-08 | Metodos para tratar deambulacion asociada a proteinopatia. |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11642352B2 (es) |
| EP (1) | EP4125879A4 (es) |
| JP (1) | JP2023518707A (es) |
| CN (1) | CN115916187A (es) |
| CA (1) | CA3170073A1 (es) |
| MX (1) | MX2022011518A (es) |
| WO (1) | WO2021194608A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3162382A1 (en) * | 2020-01-09 | 2021-07-15 | Thomas Macallister | Methods of treating cortical dementia associated wandering |
| WO2021216139A1 (en) * | 2020-04-23 | 2021-10-28 | Woolsey Pharmaceuticals, Inc | Methods of using rho kinase inhibitors to treat alzheimer's disease |
| MX2023000600A (es) * | 2020-07-14 | 2023-02-13 | Woolsey Pharmaceuticals Inc | Metodos de tratamiento de proteinopatias. |
| WO2023086468A1 (en) * | 2021-11-12 | 2023-05-19 | Woolsey Pharmaceuticals, Inc. | Method of treating amyotrophic lateral sclerosis and dosing regimen for same |
| CA3236462A1 (en) | 2021-11-29 | 2023-06-01 | Woolsey Pharmaceuticals, Inc. | Methods of treating agitation and other dementia-associated behavioral symptoms |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3464012B2 (ja) | 1993-04-05 | 2003-11-05 | 旭化成株式会社 | 精神症候治療剤 |
| WO2000009133A1 (en) * | 1998-08-10 | 2000-02-24 | Asahi Kasei Kogyo Kabushiki Kaisha | Sustained release oral preparations of fasudil hydrochloride |
| WO2005117896A1 (de) | 2004-06-03 | 2005-12-15 | Schering Aktiengesellschaft | Formulierungen, die fasudil, eine matrix und einem mantel enthalten |
| WO2008036459A2 (en) | 2006-07-20 | 2008-03-27 | Borchardt Allen J | Inhibitors of rho kinase |
| JP2010501479A (ja) | 2006-08-10 | 2010-01-21 | トランスレーショナル ジェノミクス リサーチ インスティテュート | 学習および記憶を改善するための化合物 |
| WO2008021210A2 (en) | 2006-08-11 | 2008-02-21 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
| CA2723472A1 (en) | 2008-05-12 | 2009-12-17 | Amnestix, Inc. | Compounds for rho kinase inhibition and for improving learning and memory |
| CN101612157A (zh) | 2008-06-26 | 2009-12-30 | 天津红日药业股份有限公司 | 法舒地尔诱导成年脑内源性神经干细胞再生的用途 |
| WO2013135596A1 (en) | 2012-03-12 | 2013-09-19 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Rho kinase inhibitors for use in treating amyotrophic lateral sclerosis |
| WO2017195224A1 (en) | 2016-05-09 | 2017-11-16 | Istituto Superiore Di Sanita' | Rho gtpase activating bacterial toxins for use in the treatment of disorders of the central nervous system by mucosal administration |
| CA3162382A1 (en) * | 2020-01-09 | 2021-07-15 | Thomas Macallister | Methods of treating cortical dementia associated wandering |
| WO2021216139A1 (en) * | 2020-04-23 | 2021-10-28 | Woolsey Pharmaceuticals, Inc | Methods of using rho kinase inhibitors to treat alzheimer's disease |
| MX2023000600A (es) * | 2020-07-14 | 2023-02-13 | Woolsey Pharmaceuticals Inc | Metodos de tratamiento de proteinopatias. |
-
2021
- 2021-01-08 CN CN202180036165.2A patent/CN115916187A/zh active Pending
- 2021-01-08 MX MX2022011518A patent/MX2022011518A/es unknown
- 2021-01-08 JP JP2022554548A patent/JP2023518707A/ja active Pending
- 2021-01-08 EP EP21776897.7A patent/EP4125879A4/en active Pending
- 2021-01-08 WO PCT/US2021/012587 patent/WO2021194608A1/en unknown
- 2021-01-08 CA CA3170073A patent/CA3170073A1/en active Pending
- 2021-01-08 US US17/144,802 patent/US11642352B2/en active Active
-
2023
- 2023-03-24 US US18/189,478 patent/US20230226073A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3170073A1 (en) | 2021-09-30 |
| US11642352B2 (en) | 2023-05-09 |
| US20230226073A1 (en) | 2023-07-20 |
| JP2023518707A (ja) | 2023-05-08 |
| WO2021194608A1 (en) | 2021-09-30 |
| CN115916187A (zh) | 2023-04-04 |
| EP4125879A1 (en) | 2023-02-08 |
| EP4125879A4 (en) | 2024-04-03 |
| US20210299140A1 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011518A (es) | Metodos para tratar deambulacion asociada a proteinopatia. | |
| SA521430753B1 (ar) | Kcnt1 مثبطات وطرق استخدامها | |
| SA521430751B1 (ar) | Kcnt1 مثبطات وطرق استخدامها | |
| EA201991375A1 (ru) | Бицикло[1.1.1]пентановые ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| NO961326L (no) | Inhibitorer av -amyloidproteinproduksjon | |
| NZ765495A (en) | 1, 3, 4, 5-tetrahydro-2h-pyrido[4,3-b]indole derivatives for the treatment, alleviation or prevention of disorders associated with tau aggregates like alzheimer’s disease | |
| GEP20084420B (en) | Use of imidazole compounds for the treatment of neurodegenerative disorders | |
| DE60045427D1 (de) | Bupropinmetaboliten zur Behandlung von Dementia und anderen zerebrovasckulären Erkrankungen | |
| MX2022011813A (es) | Inhibidores de kcnt1 y metodos de uso. | |
| EA201990450A1 (ru) | Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| PH12019500177A1 (en) | Treatment and prevention of sleep disorders | |
| MX2023002325A (es) | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. | |
| MX2021011488A (es) | Compuestos y usos de estos. | |
| MX2020013115A (es) | Compuestos de tetrahidrobenzofuro[2,3-c]piridina y beta-carbolina para el tratamiento, el alivio o la prevencion de trastornos asociados con los agregados de tau. | |
| MX2022011519A (es) | Metodos de uso de inhibidores de la quinasa rho para tratar demencia frontotemporal. | |
| MX2023013508A (es) | Inhibicion de la proteina de union a creb (cbp). | |
| EP4279127A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| MX2020014203A (es) | Composiciones y métodos para el tratamiento y la prevención de trastornos neurológicos. | |
| MX2024006769A (es) | Compuestos y usos de los mismos. | |
| MX2023000360A (es) | Inhibidores de kcnt1 y metodos de uso. | |
| MX2022010625A (es) | Inhibidores de kcnt1 y metodos de uso. | |
| BR112023020900A2 (pt) | Compostos tetracíclicos para tratamento de distúrbios cerebrais | |
| EA202190406A1 (ru) | Способы лечения нейродегенеративных расстройств | |
| EA202091395A1 (ru) | ПРОИЗВОДНЫЕ 1,3,4,5-ТЕТРАГИДРО-2Н-ПИРИДО[4,3-b]ИНДОЛА ДЛЯ ЛЕЧЕНИЯ, ОБЛЕГЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАССТРОЙСТВ, СВЯЗАННЫХ С АГРЕГАТАМИ ТАУ, ТАКИХ КАК БОЛЕЗНЬ АЛЬЦГЕЙМЕРА | |
| WO2024039883A3 (en) | Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms |